NAD-boosting supplement fails to improve symptoms in Parkinson’s trial
Nicotinamide riboside (NR) — an oral supplement designed to increase nicotinamide adenine dinucleotide (NAD), a molecule needed for cells to produce energy and function properly — did not improve symptoms in people with Parkinson’s disease compared with a placebo in a Phase 3 clinical trial. “We had
Source: Parkinson's News Today.